Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + Gemcitabine in Locally Advanced Pancreatic Cancer
NCT01318642Phase 2Terminated
- Sponsor
- NantBioScience
- Start
- May 2012
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing AMG 479 + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Progression-Free Survival at 181 days. Started May 2012; status: terminated.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01318642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318642.